Traders should watch for topline Phase 3 barzolvolimab CSU data in Q4 2026 and Phase 2 PN/AD readouts in mid-to-late 2026 as key catalysts. The $345M financing removes near-term dilution risk, but escalating R&D spend and lack of revenue mean the stock will trade primarily on pipeline execution.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $33.97entry
- T+1 · 6mo ago −4.97%α −5.21% · $32.28
- T+5 · 6mo ago −4.47%α −5.94% · $32.45
- T+20 · 5mo ago −15.75%α −15.77% · $28.62
- T+60 · 3mo ago +14.95%α +10.11% · $39.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting widening losses as the company invests heavily in its pipeline. Positively, the company completed enrollment six months ahead of schedule in its Phase 3 barzolvolimab CSU studies, with topline data expected in Q4 2026 and a BLA submission planned for 2027, and strengthened its balance sheet with a $345M public offering in April. The mixed report balances near-term financial deterioration against significant pipeline progress and a cash runway through 2028.
Key Financial Metrics
Key Facts
- EPS of -$1.18 vs consensus -$1.13 (miss of -4.4%)
- Revenue of $15K vs consensus $861K (miss, but pre-revenue biotech)
- Net loss widened to $78.7M from $53.8M in Q1 2025
- Enrollment completed six months ahead of guidance in Phase 3 CSU studies (EMBARQ-CSU1 and 2, n=1,939 patients)
- Topline Phase 3 CSU data expected Q4 2026; BLA filing planned for 2027
- Raised $345M in gross proceeds from a follow-on public offering in April 2026
- Cash, cash equivalents and marketable securities $451.5M at March 31, 2026
- Cash used in operating activities $65.6M in Q1 2026
- Phase 2 PN and AD studies fully enrolled; topline data expected summer/late 2026
- Phase 1 CDX-622 asthma proof-of-mechanism study ongoing
Financial Impact
Net loss of $78.7M in Q1 2026, compared to $53.8M in Q1 2025; cash balance of $451.5M supplemented by $345M offering, extending runway through 2028
Risk Factors
- Clinical trial failure or negative data in upcoming readouts
- Dilution from the April 2026 public offering (11.9M shares issued)
- Continued operating losses and cash burn ($65.6M operating cash flow in Q1)
- Competition from other chronic urticaria therapies
- Regulatory delays or setbacks for BLA submission
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290499 |
Track record
21 reports on CLDX
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers